Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results.

ABSTRACT: Despite the successful deployment of efficacious vaccines and therapeutics, the development of novel vaccines for SARS-CoV-2 remains a major goal to increase vaccine doses availability and accessibility for lower income setting. We report here on the kinetics of Spike-specific humoral and T-cell response in young and old volunteers over 6 months follow-up after a single intramuscular administration of GRAd-COV2, a gorilla adenoviral vector-based vaccine candidate currently in phase-2 of clinical development. At all three tested vaccine dosages, Spike binding and neutralizing antibodies were induced and substantially maintained up to 3 months, to then contract at 6 months. Potent T-cell responses were readily induced and sustained throughout the study period, with only minor decline. No maj

SUBMITTER: Agrati C 

PROVIDER: S-EPMC9509317 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature